Who is sponsoring NCT03550885?

NCT03550885 is sponsored by University of Illinois at Chicago.

What drugs are being tested in NCT03550885?

Interventions in NCT03550885: High taurine and saturated fat diet, Low in taurine and saturated fat diet.

What condition does NCT03550885 study?

NCT03550885 studies Colorectal Cancer.

Is NCT03550885 still recruiting?

NCT03550885 is currently completed. Last updated 6 April 2026.

Last reviewed 2026-04-06 · How we verify

NCT03550885

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diet Modulation of Bacterial Sulfur and Bile Acid Metabolism and Colon Cancer Risk

Completed NA Last updated 6 April 2026

What this trial tests

NA trial testing High taurine and saturated fat diet in Colorectal Cancer in 15 participants. Completed in 1 December 2021.

Timeline

1 August 2018

Primary endpoint
1 December 2021

1 December 2021

Quick facts

Lead sponsor	University of Illinois at Chicago
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	other
Enrollment	15
Start date	1 August 2018
Primary completion	1 December 2021
Estimated completion	1 December 2021
Sites	1 location across United States

Drugs / interventions tested

High taurine and saturated fat diet
Low in taurine and saturated fat diet

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

University of Illinois at Chicago

Who can join

Adults 45 to 75, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Determine in the context of a controlled crossover diet-intervention trial the role of taurocholic acid metabolism by gut bacteria in African American subjects at elevated risk for colorectal cancer (CRC). Two isocaloric diets, an animal-based diet high in taurine and saturated fat (HT-HSAT) and a plant-based, low in taurine and low saturated fat (LT-LSAT) will be used to determine the extent to which the relationship between diet (independent variable) and mucosal markers of CRC risk including epithelial proliferation, oxidative stress, DNA damage, and primary and secondary bile acid pools and biomarkers of inflammation (dependent variables) is explained by the abundance of sulfidogenic bacteria and hydrogen sulfide (H2S) concentrations \&/or deoxycholic acid (DCA) and DCA-producing bacteria clostridium scindens (mediator variables).

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Effects of taurocholic acid metabolism by gut bacteria: A controlled feeding trial in adult African American subjects at elevated risk for colorectal cancer.
Wolf PG, Gaskins HR, Ridlon JM, Freels S, et al · · 2020 · cited 14× · PMID 32695922 · DOI 10.1016/j.conctc.2020.100611
Diet-driven microbiome changes and physical activity in cancer patients.
Ciernikova S, Sevcikova A, Stevurkova V, Mego M. · · 2023 · cited 11× · PMID 38075222 · DOI 10.3389/fnut.2023.1285516
Role of Bacteria in the Development of Colorectal Cancer.
Thomas RM. · · 2023 · cited 4× · PMID 36844716 · DOI 10.1055/s-0042-1760679
Crosstalk Between Metabolic Reprogramming and Epigenetic Modifications in Colorectal Cancer: Mechanisms and Clinical Applications.
Sun YH, Zhang JX, Jin HS, Huang J. · · 2025 · cited 3× · PMID 41020873 · DOI 10.3390/cimb47090751
Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications.
Akter S, Madhuvilakku R, Kar AK, Nila IS, et al · · 2026 · PMID 41881983 · DOI 10.1038/s41392-026-02583-x

Verify or expand the search:

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other University of Illinois at Chicago trials

Trials by the same sponsor.

NCT07498322 — Chicago Data-driven Opioid Use Disorder Screening, Engagement, Treatment and Planning System · NA · not yet recruiting
NCT07387705 — On Track for Wellness (OTW) Stepped Wedge Cluster Randomized Trial · Phase 1 · not yet recruiting
NCT07504120 — The Effect of Remotely Delivered Pilates on Physical , and Psychological Outcomes in Individuals With Multiple Sclerosis · NA · not yet recruiting
NCT07160582 — Cognitive-Motor Training for AD/ADRD Prevention · NA · not yet recruiting
NCT07498348 — Apple Watch Evaluation of Endodontics Occupational Stress · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03550885 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Illinois at Chicago
Last refreshed: 6 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03550885.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing